Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
Tonix Pharmaceuticals published Phase 1 clinical data for TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, in the Journal of Clinical Immunology. The study of 26 healthy volunteers showed TNX-1500 was well tolerated with no serious adverse events and demonstrated dose-proportional pharmacokinetics with half-lives supporting monthly dosing. TNX-1500 successfully blocked primary and secondary T cell-dependent antibody responses, validating its mechanism of action for preventing transplant rejection.
Key figures
- Drug Name
- TNX-1500
- Phase Of Trial
- Phase 1
- Study subjects
- 26
- Half life days 10mg
- 37.8
- Half life days 30mg
- 33.8
- Dose cohorts mg per kg
- [3,10,30]
- Secondary response reduction pct
- 70
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.